UTHR: United Therapeutics Corporation - Summary | Jitta

United Therapeutics Corporation

NASDAQ:UTHR

Price
$224.78
Loss Chance
43.7%
5.64JITTA SCORE
15.71%Over Jitta Line
Jitta Ranking
30 / 1,170
450 / 5,115
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (62)
Recent Business Performance (97)
Financial Strength (78)
Return to Shareholders (41)
Competitive Advantage (64)
Jitta Signs
Recent Business PerformanceEarning Growth Last Quarter (YoY)
Debt LevelLow Long Term Debt
Revenue and EarningEarning loss detected in 2019
Operating MarginInconsistent
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.64
15.71%
1.27
129.35%
2.08
143.87%
Biotechnology
6.70
57.27%
5.44
31.32%
4.24
47.59%
COMPANY DESCRIPTION
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.